Predictive Impact of an Early Change in Serum CRP Levels in Nivolumab Therapy for mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Predictive Impact of an Early Change in Serum C-Reactive Protein Levels in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
Urol. Oncol 2019 Dec 18;[EPub Ahead of Print], H Ishihara, T Takagi, T Kondo, H Fukuda, H Tachibana, K Yoshida, J Iizuka, M Okumi, H Ishida, K TanabeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.